CY1121900T1 - Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 - Google Patents

Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2

Info

Publication number
CY1121900T1
CY1121900T1 CY20191100645T CY191100645T CY1121900T1 CY 1121900 T1 CY1121900 T1 CY 1121900T1 CY 20191100645 T CY20191100645 T CY 20191100645T CY 191100645 T CY191100645 T CY 191100645T CY 1121900 T1 CY1121900 T1 CY 1121900T1
Authority
CY
Cyprus
Prior art keywords
seq
chain variable
variable region
antibody
amino acid
Prior art date
Application number
CY20191100645T
Other languages
English (en)
Inventor
Pär Oskar Vilhelmsson TIMMERMAND
Amanda Thuy TRAN
Sven-Erik Strand
Urpo Juhani LAMMINMÄKI
Kjell SJÖSTRÖM
Original Assignee
Fredax Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1320408.6A external-priority patent/GB2520353A/en
Priority claimed from GB201401973A external-priority patent/GB201401973D0/en
Application filed by Fredax Ab filed Critical Fredax Ab
Publication of CY1121900T1 publication Critical patent/CY1121900T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει πολυπεπτίδια αντισωμάτων με εξειδίκευση δέσμευσης για ανθρώπινη καλλικρεϊνη-2 (hK2), όπου το πολυπεπτίδιο αντισώματος περιλαμβάνει (a) μεταβλητή περιοχή βαριάς αλυσίδας που περιλαμβάνει τις ακολουθίες αμινοξέων της SEQ ID NO: 1 και SEQ ID NO: 2 και SEQ ID NO: 3 ή/και (b) μεταβλητή περιοχή ελαφριάς αλυσίδας που περιλαμβάνει τις ακολουθίες αμινοξέων της SEQ ID NO: 4 και SEQ ID NO: 5 και SEQ ID NO: 6 και όπου η μεταβλητή περιοχή βαριάς αλυσίδας και η μεταβλητή περιοχή ελαφριάς αλυσίδας περιλαμβάνουν ακολουθίες αμινοξέων πλαισίου από ένα ή περισσότερα ανθρώπινα αντισώματα. Η εφεύρεση περαιτέρω παρέχει τη χρήση των εν λόγω πολυπεπτιδίων αντισωμάτων στη διάγνωση και τη θεραπεία του καρκίνου του προστάτη.
CY20191100645T 2013-11-19 2019-06-20 Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 CY1121900T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1320408.6A GB2520353A (en) 2013-11-19 2013-11-19 Antibody polypeptides and uses thereof
GB201401973A GB201401973D0 (en) 2014-02-05 2014-02-05 Antibody polypeptides and uses thereof
PCT/GB2014/053420 WO2015075445A1 (en) 2013-11-19 2014-11-19 Humanised anti kallikrein-2 antibody

Publications (1)

Publication Number Publication Date
CY1121900T1 true CY1121900T1 (el) 2020-10-14

Family

ID=52114029

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100645T CY1121900T1 (el) 2013-11-19 2019-06-20 Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2

Country Status (22)

Country Link
US (3) US10100125B2 (el)
EP (2) EP3071595B1 (el)
JP (3) JP6599859B2 (el)
KR (3) KR102574537B1 (el)
CN (2) CN105980404B (el)
AU (3) AU2014351611B2 (el)
BR (1) BR112016011025B1 (el)
CA (1) CA2930493A1 (el)
CY (1) CY1121900T1 (el)
DK (1) DK3071595T3 (el)
ES (1) ES2728515T3 (el)
HR (1) HRP20191095T1 (el)
HU (1) HUE043875T2 (el)
IL (4) IL311788A (el)
LT (1) LT3071595T (el)
MX (2) MX2016006561A (el)
PL (1) PL3071595T3 (el)
PT (1) PT3071595T (el)
RS (1) RS58831B1 (el)
RU (1) RU2687163C1 (el)
SI (1) SI3071595T1 (el)
WO (1) WO2015075445A1 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016011025B1 (pt) * 2013-11-19 2024-01-23 Fredax Ab Polipeptídeos anticorpo com especificidade de ligação para calicreina-2 humana (hk2), composição farmacêutica que os compreende e molécula de ácido nucleico
MY192513A (en) 2014-03-28 2022-08-24 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
ES2867798T3 (es) 2015-03-27 2021-10-20 Opko Diagnostics Llc Estándares del antígeno prostático y usos de estos
WO2017087826A1 (en) * 2015-11-18 2017-05-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
CA3045466A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
SG11201907208XA (en) 2017-02-10 2019-09-27 Regeneron Pharma Radiolabeled anti-lag3 antibodies for immuno-pet imaging
KR102317805B1 (ko) * 2017-03-30 2021-10-27 이씨에스-프로가스트린 에스에이 전립선암을 검출하기 위한 조성물 및 방법
CA3070796A1 (en) 2017-07-24 2019-01-31 Regeneron Pharmaceuticals, Inc. Anti-cd8 antibodies and uses thereof
AU2020273654A1 (en) 2019-05-10 2021-11-25 Janssen Biotech, Inc. Macrocyclic chelators and methods of use thereof
TW202118792A (zh) 2019-07-26 2021-05-16 美商健生生物科技公司 抗hk2嵌合抗原受體(car)
EP4004057A1 (en) 2019-07-26 2022-06-01 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
CR20220594A (es) 2020-05-27 2023-01-17 Janssen Biotech Inc Proteins comprising cd3 antigen binding domains and uses thereof
WO2022013818A1 (en) * 2020-07-17 2022-01-20 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-klk2 antibodies
US20220143231A1 (en) * 2020-11-10 2022-05-12 Janssen Biotech, Inc. Macrocyclic compounds and methods of use thereof
CN112608365B (zh) * 2020-12-22 2021-07-30 吉林省特医食品生物科技有限公司 一种减轻体重的发酵型小分子肽及其制备方法和应用
CN114790245A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
MX2023008803A (es) 2021-01-27 2023-08-04 Janssen Biotech Inc Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos.
CA3219934A1 (en) 2021-05-27 2022-12-01 Rhys Salter Compositions and methods for the treatment of prostate cancer
CA3236851A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof
CA3240194A1 (en) 2021-11-09 2023-05-19 Edward Cleator Macrocyclic compounds and methods of making the same
WO2023144723A1 (en) 2022-01-26 2023-08-03 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JP2001503991A (ja) 1996-11-14 2001-03-27 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 転移性前立腺癌の検出方法
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
AU3879200A (en) 1999-08-16 2001-03-13 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
WO2002098897A2 (en) 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
AU2002362447A1 (en) * 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
JP2007525416A (ja) 2003-01-31 2007-09-06 アルボア バイオロジクス， インコーポレイテッド 早期活性化分子のターゲティングに基づく免疫調節
EP1610818A4 (en) * 2004-03-03 2007-09-19 Millennium Pharm Inc MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
CN101094869A (zh) * 2004-08-03 2007-12-26 戴埃克斯有限公司 Hk1结合蛋白
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US8663600B2 (en) * 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
CA2598454C (en) * 2005-02-18 2013-04-09 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CN101626782B (zh) 2006-12-01 2013-03-27 梅达雷克斯公司 结合cd22的人抗体及其用途
CA2673366C (en) * 2006-12-22 2017-12-19 Phadia Ab Novel prostate kallikrein allergen
EP2347038A4 (en) * 2008-10-14 2013-06-12 Janssen Biotech Inc METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES
KR102232811B1 (ko) * 2011-10-28 2021-03-29 프레닥스 에이비 치료제 및 이의 용도
BR112016011025B1 (pt) 2013-11-19 2024-01-23 Fredax Ab Polipeptídeos anticorpo com especificidade de ligação para calicreina-2 humana (hk2), composição farmacêutica que os compreende e molécula de ácido nucleico

Also Published As

Publication number Publication date
US10100125B2 (en) 2018-10-16
EP3553088A1 (en) 2019-10-16
US20160369009A1 (en) 2016-12-22
PT3071595T (pt) 2019-06-11
AU2020207775B2 (en) 2023-06-15
JP2016540503A (ja) 2016-12-28
IL245617A0 (en) 2016-06-30
CN105980404B (zh) 2021-01-12
AU2020207775A1 (en) 2020-08-06
JP6599859B2 (ja) 2019-10-30
BR112016011025B1 (pt) 2024-01-23
KR20220020406A (ko) 2022-02-18
EP3071595A1 (en) 2016-09-28
KR102442738B1 (ko) 2022-09-15
IL245617B (en) 2021-02-28
US20190169312A1 (en) 2019-06-06
JP2020022470A (ja) 2020-02-13
IL297678B1 (en) 2024-05-01
BR112016011025A8 (pt) 2018-01-30
US20220064333A1 (en) 2022-03-03
CA2930493A1 (en) 2015-05-28
AU2014351611B2 (en) 2020-04-23
LT3071595T (lt) 2019-05-10
CN105980404A (zh) 2016-09-28
CN112898431B (zh) 2024-05-28
IL278493A (en) 2022-12-01
AU2014351611A1 (en) 2016-06-30
BR112016011025A2 (pt) 2017-12-05
DK3071595T3 (da) 2019-07-01
SI3071595T1 (sl) 2019-08-30
JP7051777B2 (ja) 2022-04-11
MX2021007006A (es) 2021-09-08
IL297678A (en) 2022-12-01
PL3071595T3 (pl) 2019-09-30
AU2023222879A1 (en) 2023-09-14
RU2016124229A (ru) 2017-12-25
KR20230132599A (ko) 2023-09-15
US11230609B2 (en) 2022-01-25
WO2015075445A1 (en) 2015-05-28
RU2687163C1 (ru) 2019-05-07
MX2016006561A (es) 2016-12-12
HUE043875T2 (hu) 2019-09-30
CN112898431A (zh) 2021-06-04
KR102574537B1 (ko) 2023-09-06
IL278493B2 (en) 2023-04-01
RS58831B1 (sr) 2019-07-31
IL311788A (en) 2024-05-01
EP3071595B1 (en) 2019-03-20
HRP20191095T1 (hr) 2019-09-20
JP2022062048A (ja) 2022-04-19
KR20160096621A (ko) 2016-08-16
ES2728515T3 (es) 2019-10-25

Similar Documents

Publication Publication Date Title
CY1121900T1 (el) Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2
CY1124771T1 (el) Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων
CY1124408T1 (el) ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ
CY1125260T1 (el) Παραγοντες δεσμευσης tigit και χρησεις τους
CY1126145T1 (el) Κατασκευασματα αντισωματων για flt3 και cd3
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
CY1120471T1 (el) Αντισωματα κατα του cd70
CY1124118T1 (el) Αντισωματα προσδεσης θυμικης στρωματικης λεμφοποιητινης (tslp) και μεθοδοι χρησης των αντισωματων
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
CY1124698T1 (el) Πρωτεϊνη δεσμευσης il-18 (il-18bp) σε φλεγμονωδεις νοσους
EA201790755A1 (ru) Модуляция стимулирующих и нестимулирующих миелоидных клеток
CY1124435T1 (el) Νουκλεικα οξεα που κωδικοποιουν ανθρωπινα αντισωματα σε sialyl-lewis α
CY1124896T1 (el) Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων
NZ711451A (en) Anti-c5 antibodies having improved pharmacokinetics
EA201791706A1 (ru) Связывающие icos белки
AR106188A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
PE20190737A1 (es) Anticuerpos anti-cd27
CY1120055T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1119149T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
JOP20190103B1 (ar) شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof